IDEAYA Amends Clinical Trial Collaboration and Supply Agreements with Pfizer to Evaluate Darovasertib + Crizotinib Combination in 1L Metastatic Uveal Melanoma
- The companies amended their collaboration to support the evaluation of the planned P-II/III registrational trial (expected to initiate in Q2’23 for 1L HLA-A2- MUM with m-PFS as 1EPs for accelerated approval) evaluating darovasertib + crizotinib and to continue support an ongoing P-II trial in the same indication
- Under the 2nd Pfizer agreement, IDEAYA will continue to receive crizotinib from Pfizer at no cost for both clinical trials as well as an additional quantity of crizotinib at a lump-sum cost (for P-II/III trial) & no cost (for P-II trial)
- Under each of the Pfizer agreement & 2nd Pfizer agreement, IDEAYA sponsors both ongoing trial & get the commercial rights in darovasertib program incl. in MUM & primary UM
Ref: PR Newswire | Image: IDEAYA
Related News:- Ideaya Expands its 2020 Collaboration and Supply Agreements with Pfizer for Darovasertib + Crizotinib to Treat Metastatic Uveal Melanoma and cMET-Driven Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at [email protected]
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].